Shanghai Pharmaceuticals Holding Co., Ltd
SHPMF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.73 | -2.94 | -6.89 | 4.99 |
| FCF Yield | 0.77% | 0.56% | 0.53% | 0.28% |
| EV / EBITDA | 37.75 | 38.40 | 32.23 | 30.77 |
| Quality | ||||
| ROIC | 4.47% | 4.49% | 6.21% | 5.88% |
| Gross Margin | 11.13% | 12.04% | 13.14% | 13.23% |
| Cash Conversion Ratio | 0.99 | 1.39 | 0.68 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.87% | 6.44% | 6.53% | 4.98% |
| Free Cash Flow Growth | 51.55% | 9.83% | 118.40% | -75.42% |
| Safety | ||||
| Net Debt / EBITDA | 1.00 | 1.14 | 0.90 | 0.82 |
| Interest Coverage | 5.01 | 4.61 | 5.34 | 5.40 |
| Efficiency | ||||
| Inventory Turnover | 6.28 | 6.25 | 5.85 | 6.91 |
| Cash Conversion Cycle | 82.50 | 122.31 | 79.45 | 74.15 |